Hollingsworth H C, Steinberg S M, Silverberg S G, Merino M J
National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Hum Pathol. 1996 Dec;27(12):1267-72. doi: 10.1016/s0046-8177(96)90335-4.
Primary transitional cell carcinoma (TCC) of the ovary has been recently recognized as a separate subtype of epithelial cancer. It has been proposed that recognition of such tumors is important on clinical grounds because of a favorable response to chemotherapy and an improved patient survival. The authors reviewed the histological and clinicopathologic findings of 58 patients with advanced stage (stages III and IV) ovarian cancer with a view to determining the frequency of TCC and confirming the favorable prognosis. Of these cases, 15 (26%) were reclassified as TCC; 13 were predominantly TCC, and 2 had a mixed pattern with approximately 50% of the tumor being TCC. TCC patients ranged in age from 44 to 70 years of age (mean, 57). Ten of the patients had stage III disease, and five were stage IV. The tumor was unilateral in 2 cases and bilateral in 11 (2 unknown). Tumor size varied between 3 and 23 cm. Of the stage III patients, five were optimally debulked, and five had residual disease. All patients received the same type of chemotherapy. The median overall survival was 28 months. There was no significant difference in the clinical outcome of patients with TCC compared with that of patients with serous carcinomas. These data suggest that TCC does not confer a favorable prognosis or better response rate to chemotherapy.
卵巢原发性移行细胞癌（TCC）最近被确认为上皮癌的一个独立亚型。有人提出，基于临床原因，识别此类肿瘤很重要，因为其对化疗反应良好且患者生存率提高。作者回顾了58例晚期（III期和IV期）卵巢癌患者的组织学和临床病理特征，以确定TCC的发生率并证实其良好的预后。在这些病例中，15例（26%）被重新分类为TCC；13例主要为TCC，2例为混合模式，肿瘤约50%为TCC。TCC患者年龄在44至70岁之间（平均57岁）。10例患者为III期疾病，5例为IV期。肿瘤单侧2例，双侧11例（2例情况不明）。肿瘤大小在3至23厘米之间。III期患者中，5例达到最佳减瘤，5例有残留病灶。所有患者接受相同类型的化疗。总生存期中位数为28个月。与浆液性癌患者相比，TCC患者的临床结局无显著差异。这些数据表明，TCC不会带来良好的预后或更高的化疗反应率。
